Collectively, these findings identify Nur77 as a critical downstream effector of lactate‐driven immune suppression in SCLC and demonstrate that targeting the LDH–H3K18La–Nur77 axis enhances the therapeutic efficacy of PD‐1 blockade by reprogramming CD8+ T cell function in the TME. Here, CD8A is linked to small cell lung carcinoma.